BPC-157: Complete Research Guide — Mechanism, Studies & White-Label Data (2026)
- Body Protection Compound-157 (BPC-157) is a synthetic 15-amino acid peptide (CAS: 137525-51-0) derived from a protective protein found in human gastric juice, first characterized in 1993.
- A 2025 systematic review identified 544 published articles spanning musculoskeletal, gastrointestinal, and neurological research applications, with 180+ PubMed results in 2025 alone — up from 45 in 2020.
- Primary mechanisms investigated include VEGFR2-mediated angiogenesis, growth hormone receptor upregulation, nitric oxide system modulation, and inflammatory cytokine reduction.
- The first human IV safety pilot study (Lee & Burgess, 2025) reported no adverse effects at doses up to 20 mg, with plasma clearance within 24 hours. No lethal dose has been identified in toxicology studies.
- BPC-157 is one of the most-requested compounds in the YPB research catalog, available for white-label resale in 5mg, 10mg, and 20mg configurations with batch-specific COAs.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (CAS: 137525-51-0), derived from a protective protein naturally present in human gastric juice. Updated March 2026. A 2025 systematic review by Vasireddi et al. identified 544 published articles from 1993–2024, with preclinical models demonstrating consistently favorable outcomes across musculoskeletal tissue repair, gastrointestinal mucosal protection, and neurological research. BPC-157 is not FDA-approved and is classified for Research Use Only (RUO).
What Is Body Protection Compound-157 and Where Does It Come From?
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide — a chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — derived from a larger protective protein naturally present in human gastric juice. Updated March 2026. First isolated and characterized by Professor Predrag Sikiric and colleagues at the University of Zagreb, Croatia, the compound’s earliest PubMed entry dates to 1993 (Sikiric et al., J Physiol Paris, 1993 — PMID: 8019625).
Key Characteristics
| Parameter | Value |
|---|---|
| Chemical Name | Pentadecapeptide BPC 157 / Bepecin |
| CAS Number | 137525-51-0 |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1,419.5 Da |
| Amino Acids | 15 (synthetic fragment of gastric juice protein) |
| Half-Life | <30 minutes (plasma clearance within 24 hours) |
| Alternative Names | PL-14736, PLD-116, PCO-02, Gastric Pentadecapeptide |
| FDA Status | Not approved. Phase II completed (ulcerative colitis) |
| WADA Status | Not listed (as of 2026) |
| Storage | Lyophilized: -20°C. Reconstituted: 2-8°C |
| Discoverer | Prof. Predrag Sikiric, University of Zagreb, Croatia (1991) |
The name “Body Protection Compound” reflects the original observation that this peptide fragment exhibited cytoprotective properties — it was identified while studying how the stomach protects its own mucosal lining from acidic digestion. Think of it this way: the stomach produces hydrochloric acid strong enough to dissolve metal, yet the stomach wall itself remains intact. Researchers investigating this paradox identified BPC-157 as one of the factors potentially contributing to that resilience.
Since its initial characterization, BPC-157 has become one of the most-studied research peptides in the world. It currently ranks as the most-searched non-weight-loss peptide in the United States, generating approximately 165,000 monthly searches as of January 2026. Researchers can source research-grade BPC-157 through the YPB catalog in multiple configurations. For broader context on how BPC-157 fits within the healing and recovery peptide category, see the Peptide Learning Center.
How Does BPC-157 Work? Primary Mechanisms of Action
Researchers have identified several interconnected biological pathways through which BPC-157 appears to exert its effects in preclinical models. The compound does not operate through a single receptor — instead, it influences multiple systems simultaneously, which is part of what makes it both scientifically fascinating and complex to study.
VEGFR2-Mediated Angiogenesis
One of the most consistently observed effects in preclinical research is BPC-157’s influence on the formation of new blood vessels. Laboratory models have demonstrated upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), a key signaling pathway in angiogenesis (Hsieh et al., J Mol Med, 2017 — PMID: 28470370). Think of an injured area as a construction zone: before rebuilding can happen, you need supply lines. BPC-157 research suggests the compound may help establish those vascular “supply routes” more rapidly in laboratory models.
Growth Hormone Receptor Upregulation
Research conducted at Chang Gung University demonstrated that BPC-157 enhanced growth hormone receptor expression in tendon fibroblasts (Chang et al., Molecules, 2014 — PMID: 25415479). Growth hormone signaling plays a central role in tissue repair and collagen synthesis. Enhanced receptor expression may mean tissue becomes more responsive to endogenous growth signals during the repair process.
Nitric Oxide System Modulation
BPC-157 research has identified close interactions with the nitric oxide (NO) system, one of the body’s primary signaling molecules for vascular regulation, inflammation modulation, and cellular communication. Multiple studies have examined how BPC-157 interacts with both the L-arginine-NO pathway and NOS (nitric oxide synthase) activity, suggesting a bidirectional modulatory role (Sikiric et al., Curr Pharm Des, 2018 — PMID: 29737246).
Inflammatory Cytokine Reduction
The 2025 systematic review by Vasireddi and colleagues found that across 36 studies meeting inclusion criteria, BPC-157 consistently demonstrated reduction of pro-inflammatory cytokines while modulating pathways involved in cell growth and angiogenesis (Vasireddi et al., Am J Sports Med, 2025 — PMID: 40756949).
What Tissue Types Has BPC-157 Been Investigated For?
Unlike many peptides studied primarily in a single tissue context, BPC-157 research spans musculoskeletal, gastrointestinal, neurological, and cardiovascular models — reflecting its multi-pathway mechanism of action.
Musculoskeletal Tissues
The largest body of preclinical evidence exists for musculoskeletal applications. The 2025 systematic review found that in preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes across muscle injury, tendon rupture, ligament tear, and bone fracture models (Vasireddi et al., 2025 — PMID: 40756949). A widely cited 2019 review by Gwyer et al. concluded that all studies investigating BPC-157 had demonstrated consistently positive and prompt healing effects across various injury types and soft tissues (Gwyer et al., Cell Tissue Res, 2019 — PMID: 30915550).
Specific findings include promotion of tendon outgrowth and cell migration (Chang et al., J Appl Physiol, 2011 — PMID: 21030672), accelerated healing in Achilles detachment models, and improved outcomes in quadriceps crush injury protocols. Researchers can source BPC-157 in 5mg, 10mg, and 20mg configurations (Research Use Only) through the YPB catalog.
Gastrointestinal Tissues
Given BPC-157’s origin as a gastric peptide, significant research has examined gastrointestinal applications. A 2025 presentation at the American College of Gastroenterology reported cytoprotective and pro-healing effects throughout the GI tract in preclinical models, including healing of GI ulcers, anastomotic sites, various GI fistulas, and inflammatory bowel disease models (Vasireddi et al., Am J Gastroenterol, 2025; Abstract S808). BPC-157 reached Phase II clinical trials for ulcerative colitis, with results indicating efficacy and no toxicity.
Neurological and Neurotransmitter Systems
A 2024 review in Current Neuropharmacology documented BPC-157’s investigated interactions with dopamine, serotonin, GABA, and glutamate pathways, noting particular anxiolytic properties in preclinical behavioral models. Researchers have also investigated BPC-157 in models of hippocampal ischemia-reperfusion injury and cuprizone-induced brain injury (Sikiric et al., Curr Neuropharmacol, 2024 — PMC: 11053547).
🧬 View BPC-157 10mg (Research Use Only) in the YPB CatalogWhat Does the Human Research Data Show So Far?
While the vast majority of BPC-157 research remains preclinical, several human data points have emerged. The total human sample size across all published studies remains very small, and no large-scale randomized controlled trials have been completed.
Ulcerative Colitis Phase II Trial
The most advanced clinical investigation was a Phase II trial for ulcerative colitis, where the compound (designated PL-14736) demonstrated efficacy with no reported toxicity. Toxicology studies established no lethal dose (LD1) (Sikiric et al., 2018 — PMID: 29737246).
Intravenous Safety Pilot Study (2025)
Lee and Burgess (2025) conducted an IRB-approved pilot study in which two healthy adults received intravenous BPC-157 at doses up to 20 mg. Cardiac, hepatic, renal, thyroid, and metabolic biomarkers showed no measurable effects. No adverse events were reported. Plasma BPC-157 concentrations returned to baseline within 24 hours, consistent with its known rapid clearance (Lee & Burgess, J Med, 2025 — PMID: 40131143).
Human Safety Summary
| Study | Route | N | Dose | Adverse Events | Year |
|---|---|---|---|---|---|
| Lee & Burgess | Intravenous | 2 | 10–20 mg | None reported | 2025 |
| Lee et al. | Intravesicular | 12 | Variable | 0 of 12 | 2024 |
| Lee & Padgett | Intraarticular | 12 | Variable | None reported | 2021 |
| Phase II (PL-14736) | Oral | Multi-site | Variable | No toxicity | Pre-2018 |
This protocol describes published research findings and is provided for educational reference. Research-grade BPC-157 from YPB is classified as Research Use Only (RUO) and is not intended for human use.
How Does BPC-157 Compare to Other Healing-Category Research Peptides?
BPC-157 is frequently discussed alongside TB-500 (Research Use Only) due to their complementary but mechanistically distinct pathways. Researchers also compare it with GHK-Cu, the fastest-growing peptide in search volume at +1,016% year-over-year growth. For researchers interested in the growth hormone axis, the Sermorelin Research Guide covers GHRH-pathway peptides in detail.
| Parameter | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Origin | Gastric juice protein | Thymosin Beta-4 | Human plasma tripeptide |
| Amino Acids | 15 | 43 | 3 |
| Primary Mechanism | VEGFR2 / NO system | G-actin sequestration | Copper-mediated gene expression |
| Key Research Focus | Tissue repair, GI, neuro | Cell migration, cardiac | Wound healing, dermal |
| PubMed Results (2025) | 180+ | ~120 | ~80 |
| Monthly US Searches | 165,000 | 74,000 | 90,500 |
| Clinical Trial Stage | Phase II | Phase II (RGN-259) | Preclinical |
| FDA Approved? | No | No | No |
If tissue repair were rebuilding a house after a storm, BPC-157 research focuses on establishing plumbing and supply lines (vascular formation via VEGFR2), while TB-500 research focuses on how building materials move to where they’re needed (cell migration via actin regulation). GHK-Cu research focuses on the blueprint activation (gene expression modulation for collagen and extracellular matrix remodeling). This mechanistic non-overlap is why combination protocols using BPC-157 and TB-500 have become one of the most frequently requested configurations.
Researchers can source the BPC-157 + TB-500 combination (Wolverine Blend) (Research Use Only) through the YPB catalog. Browse the full research catalog for pricing and documentation.
What Should Researchers Know About BPC-157 Stability and Handling?
BPC-157 is classified as a “stable” gastric pentadecapeptide — the word “stable” refers to its unusual resistance to degradation in gastric acid conditions, distinguishing it from peptides that are rapidly broken down in acidic environments. This stability is a key differentiator in the research literature.
Storage and Reconstitution Protocol
Lyophilized (freeze-dried) BPC-157 should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2-8°C and use within the timeframe appropriate for the research protocol. Avoid repeated freeze-thaw cycles. Protect from direct light exposure. Reconstitution should be performed under sterile conditions appropriate for the intended research application.
COA Verification
Research integrity depends on compound quality. Every vial used in a research protocol should be verified against a batch-specific Certificate of Analysis showing HPLC purity data, mass spectrometry confirmation, and sterility/endotoxin testing results. YourPeptideBrand.com provides batch-specific COAs for all BPC-157 products through the COA Library.
Key Research Findings: BPC-157 in 2026
- Publication momentum is accelerating. From 45 PubMed results in 2020 to 180+ in 2025, BPC-157 is attracting significantly more research attention across independent institutions.
- Musculoskeletal evidence leads. A 2025 systematic review of 36 studies (544 articles screened) demonstrated consistently improved outcomes across tendon, ligament, muscle, and bone injury models.
- Human safety data is early but favorable. Across four human investigations (IV, intravesicular, intraarticular, and oral Phase II), zero adverse events have been reported.
- Multi-pathway mechanism is unique. VEGFR2 activation, GH receptor upregulation, NO system modulation, and cytokine reduction operate in concert — distinguishing BPC-157 from single-target compounds.
- Gastric acid stability enables multi-route research. Unlike most peptides, BPC-157 has been investigated across oral, parenteral, topical, and IV routes with observed effects in each.
- Independent replication is the next frontier. The majority of early research originated from the University of Zagreb; 2025 systematic reviews from Case Western Reserve and other institutions are broadening the evidence base.
- No lethal dose identified. Toxicology studies across multiple preclinical models have not established an LD1, supporting its favorable safety profile in research contexts.
Why Is BPC-157 a High-Demand Research Compound?
The data behind BPC-157’s market position tells a compelling story for anyone evaluating the research peptide landscape from a business perspective.
Search Volume and Consumer Interest
BPC-157 generates approximately 165,000 monthly searches in the United States as of January 2026, making it the most-searched non-weight-loss research peptide. For context, this places it ahead of TB-500 (74,000/mo), GHK-Cu (90,500/mo), CJC-1295 (60,500/mo), and Ipamorelin (49,500/mo). Only GLP-1 agonists (tirzepatide, semaglutide) command higher search volume, and those occupy a different regulatory and market category entirely.
Publication Velocity
PubMed indexed 180+ BPC-157 results in 2025 alone, up from 45 in 2020 — a 4x increase in five years. The 2025 systematic reviews from Case Western Reserve University School of Medicine and a narrative review from the Medical University of Gdansk (Jozwiak et al., Pharmaceuticals, 2025 — DOI: 10.3390/ph18020185) signal that independent research institutions are expanding the evidence base beyond the original Zagreb group. This growing body of published literature gives white-label brands a credibility advantage when educating their clients.
Market Positioning Signals
| Demand Indicator | BPC-157 Data Point |
|---|---|
| Monthly US searches | 165,000 |
| PubMed publications (2025) | 180+ |
| PubMed publications (total) | 544+ articles screened (1993–2024) |
| Clinical trial stage | Phase II completed (ulcerative colitis) |
| Human safety studies | 4 published (0 adverse events) |
| YoY search growth category | Healing & Recovery (KD 4-8, low competition) |
| Combination demand | BPC-157 + TB-500 is the #1 requested pairing |
Search demand for “BPC-157 research” signals a growing market for quality-verified suppliers. The healing and recovery peptide category features significantly lower keyword difficulty scores (average KD 4-8) compared to the weight-loss category (KD 20-35), representing high-ROI positioning for new brands entering the space.
How Can You Offer BPC-157 Under Your Own Brand?
YourPeptideBrand.com’s white-label model lets you offer BPC-157 (Research Use Only) under your own brand without managing inventory, sourcing, testing, or fulfillment. Your brand, your pricing, your client relationships — YPB operates behind the scenes.
What White-Labeling Means
You operate a branded storefront (cloned from YPB’s proven template, live within 7 days of signing up). When a client orders BPC-157 from your site, YPB fulfills the order with branded packaging and ships directly to your client. Every batch ships with a Certificate of Analysis your clients can verify through the COA Library. No inventory risk — YPB dropships directly under your brand.
BPC-157 Wholesale Pricing & Margin Analysis
| SKU | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|
| BPC-157 5mg (.212) | $26.68 | $32.01 | $50.00 | $23.32 |
| BPC-157 10mg (.213) | $33.59 | $40.31 | $100.00 | $66.41 |
| BPC-157 20mg (.237) | $57.77 | $69.33 | $180.00 | $122.23 |
| Wolverine 5mg (.216) | $47.41 | $56.89 | $100.00 | $52.59 |
| Wolverine 10mg (.217) | $78.51 | $94.21 | $180.00 | $101.49 |
At suggested retail, BPC-157 10mg generates $66.41 margin per unit for Premier members — and as one of the most frequently sourced compounds in the catalog, it represents a high-volume, high-margin anchor product for any white-label brand. See the full catalog for all 60+ SKUs and volume pricing.
Who This Is For
BPC-157 is frequently sourced by clinics, research suppliers, wellness entrepreneurs, and compounding pharmacy partners. YPB provides turnkey white-label fulfillment: branded packaging, COA documentation, compliance support, and dropship logistics. Join 250+ white-label research brands already operating on the YPB platform.
Book a call to discuss your white-label research brand or download the product catalog for complete pricing and SKU details.
Methodology & Data Sources
Scientific literature: PubMed, Embase, and Cochrane databases searched for “BPC-157” and all known alternative designations (PL-14736, PLD-116, PCO-02, gastric pentadecapeptide, bepecin). Search conducted through March 2026.
Systematic reviews: Vasireddi et al. (2025) from Case Western Reserve University School of Medicine, encompassing 544 articles screened per PRISMA guidelines. Gwyer et al. (2019) critical review from Keele University. Jozwiak et al. (2025) literature and patent review from Medical University of Gdansk.
Search volume data: Google Ads keyword data via DataForSEO, January 2026, as reported by The Peptide Effect’s State of Peptides 2026 report.
Pricing data: YPB Full Pricing Catalog, current as of March 2026. Premier ($497/mo) and Core ($297/mo) membership tiers.
Limitations: The majority of cited studies are preclinical. Human data is limited to small-sample studies. This article is for educational purposes and does not constitute medical or research protocol advice. Search volume figures are estimates from Google Ads keyword data and may not reflect actual search volumes precisely.
References
- Vasireddi, N., Hahamyan, H., Salata, M.J., Karns, M., Calcei, J.G., Voos, J.E., & Apostolakos, J.M. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. American Journal of Sports Medicine. PMID: 40756949
- Lee, J.J. & Burgess, L. (2025). Safety of intravenous infusion of BPC157 in humans: A pilot study. Journal of Medicine, 31(5), 20–24. PMID: 40131143
- Jozwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide—Literature and patent review. Pharmaceuticals, 18(2), 185. DOI: 10.3390/ph18020185
- Gwyer, D., Wragg, N.M., & Wilson, S.L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377, 153–159. PMID: 30915550
- Chang, C.H., Tsai, W.C., Hsu, Y.H., & Pang, J.H.S. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19, 19066–19077. PMID: 25415479
- Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., & Pang, J.H.S. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110, 774–780. PMID: 21030672
- Hsieh, M.J., Liu, H.T., Wang, C.N., et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. PMID: 28470370
- Sikiric, P., et al. (2018). The stable gastric pentadecapeptide BPC 157—pleiotropic beneficial activity. Current Pharmaceutical Design, 24(18). PMID: 29737246
- Sikiric, P., et al. (2024). The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity and its possible relations with neurotransmitter activity. Current Neuropharmacology. PMC: 11053547
Frequently Asked Questions
What is BPC-157 and what does it do in research models?
BPC-157 (Body Protection Compound-157, CAS: 137525-51-0) is a synthetic 15-amino acid peptide derived from human gastric juice proteins. Preclinical research has investigated its effects on tissue repair, angiogenesis, inflammatory cytokine modulation, and gastrointestinal mucosal protection. It is classified for Research Use Only (RUO) and is not FDA-approved.
How many published studies exist on BPC-157 as of 2026?
A 2025 systematic review by Vasireddi et al. identified 544 articles from 1993 to 2024 across PubMed, Cochrane, and Embase. PubMed indexed over 180 BPC-157 results in 2025 alone, representing a 4x increase from 45 results in 2020. The compound has been investigated across musculoskeletal, gastrointestinal, and neurological research applications.
What is the difference between BPC-157 and TB-500 in research contexts?
BPC-157 is a 15-amino acid gastric peptide that operates primarily through VEGFR2-mediated angiogenesis and nitric oxide system modulation. TB-500 is a 43-amino acid fragment of Thymosin Beta-4 that functions through G-actin sequestration to promote cell migration. Researchers study them together because their mechanisms do not overlap, potentially providing complementary data in tissue repair models.
What is BPC-157’s half-life and stability profile?
BPC-157 has a plasma half-life of less than 30 minutes with complete clearance within 24 hours. It is classified as “stable” because it resists degradation in gastric acid conditions, unlike most peptides. Lyophilized BPC-157 should be stored at -20°C; reconstituted solutions at 2-8°C.
Has BPC-157 been investigated in human studies?
Four human investigations have been published: a Phase II trial for ulcerative colitis (no toxicity reported), an intraarticular study in 12 subjects (Lee & Padgett, 2021), an intravesicular study in 12 subjects (Lee et al., 2024), and an IV pilot study in 2 adults at doses up to 20 mg (Lee & Burgess, 2025). Zero adverse events have been reported across all studies, though total sample sizes remain small.
Can I offer BPC-157 under my own brand through YPB?
Yes. YourPeptideBrand.com provides a white-label dropship model where BPC-157 (Research Use Only) is fulfilled under your brand. Your store can be live within 7 days. Premier members ($497/mo) access BPC-157 10mg at $33.59 wholesale with a suggested MSRP of $100 — generating $66.41 margin per unit. Every batch includes a COA your clients can verify.
What documentation comes with white-label BPC-157?
Every BPC-157 batch ships with a Certificate of Analysis (COA) documenting HPLC purity, mass spectrometry identity confirmation, and endotoxin testing results. COAs are accessible through the YPB COA Library and can be shared directly with your clients for research verification.
What margin can I expect on BPC-157 as a white-label brand?
Premier members access BPC-157 5mg at $26.68 (MSRP $50, margin $23.32), BPC-157 10mg at $33.59 (MSRP $100, margin $66.41), and BPC-157 20mg at $57.77 (MSRP $180, margin $122.23). The Wolverine Blend (BPC-157 + TB-500) 10mg is available at $78.51 wholesale (MSRP $180, margin $101.49). Volume pricing is available for high-throughput research suppliers.
Key Takeaways
Research Takeaways
- 544+ articles have been published since 1993, with 180+ in 2025 alone — a 4x increase from 2020.
- Multi-pathway mechanism (VEGFR2, GH receptor, NO system, cytokine modulation) distinguishes BPC-157 from single-target research compounds.
- Musculoskeletal evidence is strongest: A 2025 systematic review of 36 studies showed consistently improved outcomes across tendon, ligament, muscle, and bone models.
- Phase II clinical data exists for ulcerative colitis with no reported toxicity and no lethal dose identified.
- Four human safety studies (total: ~28 subjects) report zero adverse events across IV, intraarticular, intravesicular, and oral routes.
- Gastric acid stability enables multi-route research — a rare property among peptides.
- Independent replication is expanding: 2025 systematic reviews from Case Western Reserve and Gdansk are broadening the evidence base beyond the original Zagreb group.
- BPC-157 + TB-500 combination is the most-studied peptide pairing in healing research due to non-overlapping mechanisms.
Business Takeaways
- BPC-157 represents a high-demand, high-margin research compound for white-label brands. At 165,000 monthly US searches, it is the most-searched non-weight-loss peptide — and it sits in a low-competition keyword category (KD 4-8).
- Premier members access BPC-157 10mg at $33.59 wholesale with $66.41+ margin per unit at suggested MSRP. The 20mg configuration yields $122.23 per unit.
- YPB provides turnkey white-label fulfillment: branded packaging, COA documentation, compliance support, and dropship logistics for 250+ active storefronts.
Ready to discuss your research needs? Book a consultation with our team.
